Design: Phase 3, randomised, open-label, 52-week safety study
Population: 401 Japanese adults with type 2 diabetes on diet and exercise or 1-2 oral agents
Primary outcome: Treatment-emergent adverse events over 52 weeks
Effect: Adverse events in 85%; discontinuations 5% (3 mg) to 14% (36 mg); no severe hypoglycaemia

ACHIEVE-J tested the oral GLP-1 receptor agonist orforglipron for safety in 401 Japanese adults with type 2 diabetes, randomised to 3, 12 or 36 mg once daily on top of diet and exercise or one or two oral agents. The primary endpoint was safety over 52 weeks, not glucose lowering, and the trial was open-label.

Treatment-emergent adverse events occurred in 85% of participants, mostly mild or moderate and gastrointestinal. Discontinuation for adverse events tracked with dose, rising from 5% at 3 mg to 14% at 36 mg, and gastrointestinal symptoms were the usual reason. No severe hypoglycaemia occurred at any dose.

An oral GLP-1 agonist matters because it removes the injection barrier that keeps some patients off this class. The open question this study frames rather than answers is tolerability at the dose that lowers glucose most. Orforglipron's regulatory position in India is not yet established; treat availability as unknown for now.

401 Japanese adults with type 2 diabetes, randomised to orforglipron 3, 12 or 36 mg once daily.
The primary endpoint was safety over 52 weeks, not glucose lowering.
Treatment-emergent adverse events occurred in 85%, mostly mild or moderate and gastrointestinal.
Discontinuation for adverse events rose with dose, from 5% at 3 mg to 14% at 36 mg.
No severe hypoglycaemia occurred at any dose.

Why it matters

An oral GLP-1 would remove the injection barrier; whether patients tolerate the dose that works is the open question.

The statistics, in plain English

Because this was a safety study, the percentages describe side-effects rather than glucose control. The rise in discontinuations from 5% to 14% across doses shows tolerability falls as the dose climbs; this was a descriptive comparison, not a formal test of one dose against another.